Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2401 to 2415 of 8915 results

  1. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]

    In development Reference number: GID-TA11674 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  2. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]

    Awaiting development Reference number: GID-TA11639 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637]

    Awaiting development Reference number: GID-TA11840 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Ondansetron for treating alcohol-use disorder [ID6341]

    Awaiting development Reference number: GID-TA11375 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-IPG10448 Expected publication date:  15 October 2026

    Interventional procedures guidance
    In development

  6. ID6611 Obesity, overweight - semaglutide (including review of TA875)

    Awaiting development Reference number: GID-TA11851 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]

    Awaiting development Reference number: GID-TA11052 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]

    Awaiting development Reference number: GID-TA11758 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]

    Awaiting development Reference number: GID-TA11198 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Head injury (QS74) update

    In development Reference number: GID-QS10189 Expected publication date:  07 January 2027

    Quality standard
    In development

  11. Osteoporosis

    In development Reference number: GID-QS10188 Expected publication date: TBC

    Quality standard
    In development

  12. AHEAD implants for external ear prosthesis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  13. Intradiscal oxygen-ozone treatment of symptomatic lumbar disc herniation

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  14. Insertion of Stoma Preservation Device

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  15. Botulinum Toxin injection prior to Abdominal wall reconstruction

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation